Javitt Jonathan C's Form 4/A amendment
AmendedNRX Pharmaceuticals, Inc. (NRXP) · filed Jun 2, 2022
- Accession no.
- 0000921895-22-001874
- Filed
- Jun 2, 2022
- Trade date
- Jun 1, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jun 2, 2022
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $58.0K. It was filed 1 day after the trade.
This amendment replaces 0000921895-22-001872 (filed Jun 2, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Javitt Jonathan CCIK 0001303782 | Director, Officer (Chief Scientist), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2022 | Common Stock | PPurchaseAcquired | +100,000 | $0.58 | +$58,000 | 146,332 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.